Literature DB >> 16632201

Increased frequency of the LRRK2 G2019S mutation in an elderly Ashkenazi Jewish population is not associated with dementia.

Rachel Saunders-Pullman1, Richard B Lipton, Geetha Senthil, Mindy Katz, Camille Costan-Toth, Carol Derby, Susan Bressman, Joe Verghese, Laurie J Ozelius.   

Abstract

Mutations in leucine-rich repeat kinase 2 gene (LRRK2) have been associated with idiopathic Parkinson's disease (PD), as well as pleomorphic neurodegenerative pathology, including Alzheimer's disease. One specific LRRK2 mutation, G2019S, was reported in 18% of people with PD of Ashkenazi descent, supporting a founder effect in this population. To determine if this mutation is also associated with dementia in the Ashkenazim, we screened 192 elderly Ashkenazi Jewish (AJ) individuals in a longitudinal aging and cognition study, of whom 49 (25.5%) had dementia. Two non-demented individuals harbored the mutation (2/143, 1.4%), but no individuals with dementia. Neither person with the mutation had Parkinson's disease. Therefore, the LRRK2 mutation has a relatively high frequency in the AJ population, is not fully penetrant for parkinsonism in the elderly, and does not appear to be commonly associated with late-onset dementia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16632201     DOI: 10.1016/j.neulet.2006.03.044

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

1.  Gender differences in the risk of familial parkinsonism: beyond LRRK2?

Authors:  R Saunders-Pullman; K Stanley; M San Luciano; M J Barrett; V Shanker; D Raymond; L J Ozelius; S B Bressman
Journal:  Neurosci Lett       Date:  2011-04-12       Impact factor: 3.046

Review 2.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Clinical expression of LRRK2 G2019S mutations in the elderly.

Authors:  Marta San Luciano; Richard B Lipton; Cuiling Wang; Mindy Katz; Molly E Zimmerman; Amy E Sanders; Laurie J Ozelius; Susan B Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

Review 4.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

5.  Human LRRK2 G2019S mutation represses post-synaptic protein PSD95 and causes cognitive impairment in transgenic mice.

Authors:  Samuel O Adeosun; Xu Hou; Baoying Zheng; Heather L Melrose; Thomas Mosley; Jun Ming Wang
Journal:  Neurobiol Learn Mem       Date:  2017-05-06       Impact factor: 2.877

6.  Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.

Authors:  Liang Huang; Mika Shimoji; Juan Wang; Salim Shah; Sukanta Kamila; Edward R Biehl; Seung Lim; Allison Chang; Kathleen A Maguire-Zeiss; Xiaomin Su; Howard J Federoff
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

7.  Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.

Authors:  Yanping Li; Wencheng Liu; Tinmarla F Oo; Lei Wang; Yi Tang; Vernice Jackson-Lewis; Chun Zhou; Kindiya Geghman; Mikhail Bogdanov; Serge Przedborski; M Flint Beal; Robert E Burke; Chenjian Li
Journal:  Nat Neurosci       Date:  2009-06-07       Impact factor: 24.884

8.  Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.

Authors:  Anat Mirelman; Rachel Saunders-Pullman; Roy N Alcalay; Shiran Shustak; Avner Thaler; Tanya Gurevich; Deborah Raymond; Helen Mejia-Santana; Martha Orbe Reilly; Laurie Ozelius; Lorraine Clark; Mali Gana-Weisz; Anat Bar-Shira; Avi Orr-Utreger; Susan B Bressman; Karen Marder; Nir Giladi
Journal:  Mov Disord       Date:  2018-03-30       Impact factor: 10.338

Review 9.  Leucine-rich repeat kinase 2-linked Parkinson's disease: clinical and molecular findings.

Authors:  Udhaya Kumari; Eng-King Tan
Journal:  J Mov Disord       Date:  2010-10-30

Review 10.  Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Authors:  Elisa Greggio; Mark R Cookson
Journal:  ASN Neuro       Date:  2009-04-14       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.